Carlos H Barcenas
Overview
Explore the profile of Carlos H Barcenas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin-Cho L, Choi E, Dawkins-Moultin L, Wong C, Borjas M, Fei F, et al.
Eur J Oncol Nurs
. 2025 Jan;
74:102790.
PMID: 39813977
Purpose: Rural breast cancer survivors (BCS) have unique unmet psychosocial needs that affect quality of life (QOL). Expressive writing (EW) has been shown to improve QOL in cancer survivors, however,...
2.
Yennurajalingam S, Valero V, Smalgo B, Overman M, Dasari A, Wolff R, et al.
J Natl Compr Canc Netw
. 2025 Jan;
23(1.
PMID: 39773433
Background: Physical activity (PA) and dexamethasone (Dex) when used independently have modest benefits for cancer-related fatigue (CRF) in patients with advanced cancer. In this study we aimed to determine the...
3.
Reddy J, Sherry A, Fellman B, Liu S, Bathala T, Haymaker C, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):885-893.
PMID: 39486645
Purpose: Prior evidence suggests a progression-free survival (PFS) benefit from adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy for patients with some oligometastatic solid tumors. Randomized trials testing this...
4.
Shin-Cho L, Dawkins-Moultin L, Choi E, Chen M, Barcenas C, Roth M, et al.
J Adolesc Young Adult Oncol
. 2024 Oct;
PMID: 39466058
Many young adult (YA) breast cancer survivors (BCS) experience psychosocial distress during and after treatment, but do not utilize supportive care resources to maximize their health outcomes. The purpose of...
5.
Jayan A, Sukumar J, Fangman B, Patel T, Raghavendra A, Liu D, et al.
JCO Oncol Pract
. 2024 Oct;
:OP2400371.
PMID: 39388649
Purpose: The addition of pembrolizumab to chemotherapy in high-risk early triple-negative breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied immune-related adverse events (irAEs) where some can be severe...
6.
Chen J, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, et al.
BMC Cancer
. 2024 Aug;
24(1):1016.
PMID: 39148033
Background: Triple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) could predict response...
7.
George G, Andersen C, Tang X, Rodriguez E, Jafry M, Swartz M, et al.
J Natl Compr Canc Netw
. 2024 Jul;
22(6.
PMID: 38996438
Background: The overall landscape of health-related quality of life (HRQoL) has not been thoroughly investigated in adolescents and young adults (AYAs) with cancer. Data are also lacking on how well...
8.
Raghavendra A, Liu D, Shen Y, Barcenas C, Ueno N, Giordano S, et al.
Breast Cancer Res Treat
. 2024 Jun;
207(1):81-90.
PMID: 38916821
Background: Despite lower chemotherapy use in older triple-negative breast cancer (TNBC) patients, their outcomes match younger counterparts. We compared outcomes in early-stage TNBC patients by age receiving chemotherapy at a...
9.
Woodfin A, Yam C, Teshome M, Kuerer H, Hunt K, Meric-Bernstam F, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):974-980.
PMID: 37973647
Background: Triple-negative breast cancer (TNBC) is known to portend a worse prognosis compared with same-stage, hormone receptor-positive disease. However, with the recent change in practice to include pembrolizumab in neoadjuvant...
10.
Chido-Amajuoyi O, Onyeaka H, Sokale I, Nwani S, Barcenas C, Amonoo H, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2341191.
PMID: 37921773
No abstract available.